A. Carella

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)

H. Gschaidmeier, C. Huber, T. Fischer, 2002, Leukemia.

Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.

M. Gobbi, A. Bacigalupo, L. Canepa, 2002, Journal of experimental & clinical cancer research : CR.

Chronic Myeloid Leukaemia - The Choice of Therapy and Future Perspectives

A. Ibatici, A. Carella, C. Ghiggi, 2015 .

Inhibition of autophagy with clarithromycin: a new strategy to enhance sensitivity of CML stem cells to tyrosine kinase inhibitors.

A. Garuti, G. Pica, C. Ghiggi, 2012, Leukemia supplements.

Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.

E. Molinari, M. Gobbi, M. Miglino, 2015, Leukemia research.

Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia

A. Carella, G. Pica, G. Catania, 2012, Leukemia & lymphoma.

Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD)

A. Carella, G. Beltrami, P. Scalzulli, 2004, Bone Marrow Transplantation.